Incyte Corp. Rating Reiterated by Jefferies Group (INCY)
Incyte Corp. (NASDAQ:INCY)‘s stock had its “buy” rating restated by Jefferies Group in a research note issued on Monday, American Banking & Market News reports.
Incyte Corp. (NASDAQ:INCY) opened at 35.66 on Monday. Incyte Corp. has a 1-year low of $15.43 and a 1-year high of $38.52. The stock’s 50-day moving average is $32.36 and its 200-day moving average is $24.88. The company’s market cap is $5.458 billion.
Incyte Corp. (NASDAQ:INCY) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.05 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.08 by $0.03. The company had revenue of $101.70 million for the quarter, compared to the consensus estimate of $114.34 million. During the same quarter last year, the company posted $0.03 earnings per share. Incyte Corp.’s revenue was up 17.6% compared to the same quarter last year. Analysts expect that Incyte Corp. will post $-0.35 EPS for the current fiscal year.
A number of other firms have also recently commented on INCY. Analysts at Oppenheimer reiterated a “buy” rating on shares of Incyte Corp. (NASDAQ:INCY) in a research note to investors on Friday. They now have a $43.00 price target on the stock. Separately, analysts at Barclays Capital raised their price target on shares of Incyte Corp. (NASDAQ:INCY) from $22.00 to $36.00 in a research note to investors on Friday. They now have an “equal weight” rating on the stock. Finally, analysts at Argus raised their price target on shares of Incyte Corp. (NASDAQ:INCY) from $28.00 to $45.00 in a research note to investors on Thursday, September 12th. They now have a “buy” rating on the stock.
Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating to the company’s stock. Incyte Corp. currently has an average rating of “Buy” and an average price target of $35.00.
In other Incyte Corp. news, CEO Paul A. Friedman unloaded 376,789 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $37.32, for a total value of $14,061,765.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.